Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder

Masoud Khorsand, Joan Lange, Lynn G Feun, Neil J. Clendeninn, Mary Collier, George Wilding

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Oral piritrexim (PTX), a second generation antimetabolite, has been shown to be an active agent against methotrexate refractory transitional cell cancer (TCC) of the bladder in phase I trials. We conducted a phase II trial of this drug in patients with TCC of the bladder who failed a first line chemotherapy regimen. Methods: Oral PTX was started at the dose of 25 mg three times per day for 5 days weekly for 3 weeks followed by one week of rest. If this was tolerated the dose was increased to 50 mg three times a day. Patients were monitored for response rate and toxicity. Results: Seventeen patients were entered into the trial. Two patients did not complete the required 2 courses of treatment to be evaluable. There were 13 evaluable patients. Among the 13 no one achieved a complete response (CR), however, there were 3 partial responses (PRs = RR: 23%) and 5 stable diseases (SDs). The responses lasted 2, 8 and 14 months. The major dose-limiting toxicity was myelosuppression. Two patients died on treatment. One death was due to neutropenic fever and the cause of death in the second patient is thought to be a cerebral vascular accident (CVA). Conclusion: PTX is an active drug in the treatment of TCC of the bladder. Bone marrow suppression is the most common dose-limiting toxicity. In view of the observed responses and toxicities in this study and other studies, we suggest that the role of PTX be further investigated in the following clinical settings: 1. Palliative initial treatment in patients with TCC of the bladder who are not candidates for more aggressive chemotherapy. 2. As first line chemotherapy in combination with other active drugs.

Original languageEnglish
Pages (from-to)157-163
Number of pages7
JournalInvestigational New Drugs
Volume15
Issue number2
DOIs
StatePublished - Jun 25 1997

Fingerprint

Urinary Bladder Neoplasms
Pharmaceutical Preparations
Antimetabolites
Drug Therapy
piritrexim
Combination Drug Therapy
Palliative Care
Methotrexate
Accidents
Blood Vessels
Cause of Death
Fever
Therapeutics
Bone Marrow

Keywords

  • Aged
  • Bladder neoplasm
  • Tetrahydrofolate dehydrogenase inhibitor

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. / Khorsand, Masoud; Lange, Joan; Feun, Lynn G; Clendeninn, Neil J.; Collier, Mary; Wilding, George.

In: Investigational New Drugs, Vol. 15, No. 2, 25.06.1997, p. 157-163.

Research output: Contribution to journalArticle

Khorsand, Masoud ; Lange, Joan ; Feun, Lynn G ; Clendeninn, Neil J. ; Collier, Mary ; Wilding, George. / Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. In: Investigational New Drugs. 1997 ; Vol. 15, No. 2. pp. 157-163.
@article{cd3ba35f3190479195aca3f80af8e113,
title = "Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder",
abstract = "Oral piritrexim (PTX), a second generation antimetabolite, has been shown to be an active agent against methotrexate refractory transitional cell cancer (TCC) of the bladder in phase I trials. We conducted a phase II trial of this drug in patients with TCC of the bladder who failed a first line chemotherapy regimen. Methods: Oral PTX was started at the dose of 25 mg three times per day for 5 days weekly for 3 weeks followed by one week of rest. If this was tolerated the dose was increased to 50 mg three times a day. Patients were monitored for response rate and toxicity. Results: Seventeen patients were entered into the trial. Two patients did not complete the required 2 courses of treatment to be evaluable. There were 13 evaluable patients. Among the 13 no one achieved a complete response (CR), however, there were 3 partial responses (PRs = RR: 23{\%}) and 5 stable diseases (SDs). The responses lasted 2, 8 and 14 months. The major dose-limiting toxicity was myelosuppression. Two patients died on treatment. One death was due to neutropenic fever and the cause of death in the second patient is thought to be a cerebral vascular accident (CVA). Conclusion: PTX is an active drug in the treatment of TCC of the bladder. Bone marrow suppression is the most common dose-limiting toxicity. In view of the observed responses and toxicities in this study and other studies, we suggest that the role of PTX be further investigated in the following clinical settings: 1. Palliative initial treatment in patients with TCC of the bladder who are not candidates for more aggressive chemotherapy. 2. As first line chemotherapy in combination with other active drugs.",
keywords = "Aged, Bladder neoplasm, Tetrahydrofolate dehydrogenase inhibitor",
author = "Masoud Khorsand and Joan Lange and Feun, {Lynn G} and Clendeninn, {Neil J.} and Mary Collier and George Wilding",
year = "1997",
month = "6",
day = "25",
doi = "10.1023/A:1005860806635",
language = "English",
volume = "15",
pages = "157--163",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder

AU - Khorsand, Masoud

AU - Lange, Joan

AU - Feun, Lynn G

AU - Clendeninn, Neil J.

AU - Collier, Mary

AU - Wilding, George

PY - 1997/6/25

Y1 - 1997/6/25

N2 - Oral piritrexim (PTX), a second generation antimetabolite, has been shown to be an active agent against methotrexate refractory transitional cell cancer (TCC) of the bladder in phase I trials. We conducted a phase II trial of this drug in patients with TCC of the bladder who failed a first line chemotherapy regimen. Methods: Oral PTX was started at the dose of 25 mg three times per day for 5 days weekly for 3 weeks followed by one week of rest. If this was tolerated the dose was increased to 50 mg three times a day. Patients were monitored for response rate and toxicity. Results: Seventeen patients were entered into the trial. Two patients did not complete the required 2 courses of treatment to be evaluable. There were 13 evaluable patients. Among the 13 no one achieved a complete response (CR), however, there were 3 partial responses (PRs = RR: 23%) and 5 stable diseases (SDs). The responses lasted 2, 8 and 14 months. The major dose-limiting toxicity was myelosuppression. Two patients died on treatment. One death was due to neutropenic fever and the cause of death in the second patient is thought to be a cerebral vascular accident (CVA). Conclusion: PTX is an active drug in the treatment of TCC of the bladder. Bone marrow suppression is the most common dose-limiting toxicity. In view of the observed responses and toxicities in this study and other studies, we suggest that the role of PTX be further investigated in the following clinical settings: 1. Palliative initial treatment in patients with TCC of the bladder who are not candidates for more aggressive chemotherapy. 2. As first line chemotherapy in combination with other active drugs.

AB - Oral piritrexim (PTX), a second generation antimetabolite, has been shown to be an active agent against methotrexate refractory transitional cell cancer (TCC) of the bladder in phase I trials. We conducted a phase II trial of this drug in patients with TCC of the bladder who failed a first line chemotherapy regimen. Methods: Oral PTX was started at the dose of 25 mg three times per day for 5 days weekly for 3 weeks followed by one week of rest. If this was tolerated the dose was increased to 50 mg three times a day. Patients were monitored for response rate and toxicity. Results: Seventeen patients were entered into the trial. Two patients did not complete the required 2 courses of treatment to be evaluable. There were 13 evaluable patients. Among the 13 no one achieved a complete response (CR), however, there were 3 partial responses (PRs = RR: 23%) and 5 stable diseases (SDs). The responses lasted 2, 8 and 14 months. The major dose-limiting toxicity was myelosuppression. Two patients died on treatment. One death was due to neutropenic fever and the cause of death in the second patient is thought to be a cerebral vascular accident (CVA). Conclusion: PTX is an active drug in the treatment of TCC of the bladder. Bone marrow suppression is the most common dose-limiting toxicity. In view of the observed responses and toxicities in this study and other studies, we suggest that the role of PTX be further investigated in the following clinical settings: 1. Palliative initial treatment in patients with TCC of the bladder who are not candidates for more aggressive chemotherapy. 2. As first line chemotherapy in combination with other active drugs.

KW - Aged

KW - Bladder neoplasm

KW - Tetrahydrofolate dehydrogenase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0030927578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030927578&partnerID=8YFLogxK

U2 - 10.1023/A:1005860806635

DO - 10.1023/A:1005860806635

M3 - Article

C2 - 9220296

AN - SCOPUS:0030927578

VL - 15

SP - 157

EP - 163

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -